Skip to Content

Why Half the World Will Be Short-Sighted by 2050 — Children's Eyes & the Myopia Epidemic

7 April 2026 by
Why Half the World Will Be Short-Sighted by 2050 — Children's Eyes & the Myopia Epidemic
AGAAZ OPHTHALMICS, Girish Dave
Why Half the World Will Be Short-Sighted by 2050 — and What's Happening to Children's Eyes Right Now | Agaaz Ophthalmics
Beyond Vision · Global Eye Health · April 2026

Why Half the World
Will Be Short-Sighted
by 2050 And what is happening to children's eyes right now

The myopia epidemic is not a projection problem. It is here, accelerating, and the biology behind it is something every parent, teacher, and eye doctor should understand before the next generation reaches adulthood.

5 billionPeople expected to
have myopia by 2050
Rise in urban Indian
child myopia in 20 years
10×Higher retinal detachment
risk with high myopia
The Context

Something is wrong with how the world's children are seeing. Not metaphorically — physically. The proportion of human beings who cannot focus on distant objects without corrective lenses has roughly doubled in the last 25 years, and projections suggest it will keep climbing until, by 2050, roughly half of everyone alive will be myopic. This is not a natural variation in human visual capability. It is an environmental epidemic with identifiable causes, measurable progression, and — crucially — preventable outcomes.

The conversation around myopia has long been framed as a convenience problem: get glasses, buy contact lenses, consider LASIK at 21. Problem solved. This framing misses something important. High myopia — beyond a certain threshold — is not a refractive inconvenience. It is a structural pathology that raises the risk of retinal detachment, macular degeneration, glaucoma, and early cataract by factors of 3 to 10 or more. Glasses correct the blur. They do not stop the underlying biology.

Understanding what is actually happening inside a myopic eye — and why it happens faster in children who read on screens, study indoors, and sleep too little — is the first step toward acting on it. This article makes that case clearly, with the best available 2025–2026 evidence, and with specific attention to India's situation.

🔭

This is not just a glasses problem

The global rise in myopia is one of the most significant preventable public health crises in ophthalmology today. It disproportionately affects children in urbanised, high-education environments. And it is accelerating. Every year that intervention is delayed represents another cohort of children whose eyes will have elongated further than they needed to — a structural change that cannot be undone.

Layer 1 — Biology

What myopia actually is — and why it cannot be reversed

Myopia — nearsightedness — occurs when the eye is too long for its optical power. Light from distant objects focuses in front of the retina instead of on it, producing a blurred image. The correction is simple: a concave lens shifts the focal point back. What is less simple is the structural reality underneath.

In most cases, myopia results from axial elongation — the eyeball physically grows too long. A normal adult eye has an axial length of approximately 23–24mm. Every additional millimetre of axial length corresponds to roughly 2.5–3 dioptres of myopia. An eye with -6D of myopia may be 26mm long — a difference that sounds trivial in millimetres but represents significant structural stress on the tissues at the back of the eye, particularly the retina and its supporting blood vessels.

"The global prevalence of myopia has surged from 22.9% in 2000 to an estimated 34% in 2020 and is expected to reach 50% by 2050, affecting nearly 5 billion people. The rate of increase is too rapid to be explained by hereditary shifts — environmental factors are the primary drivers."

— Ophthalmology Times Europe · April 2026 · Citing Liang et al., Br J Ophthalmol 2025

The critical biological point is this: axial elongation is irreversible. Once the eye has grown longer, it does not grow shorter. Corrective lenses manage the optical consequences. They do not change the structural reality. This is why myopia management — slowing the rate of elongation during childhood, when the eye is most active in its growth — matters so much more than correction after the fact.

The eye does most of its growing between ages 5 and 15. During this window, the rate of axial elongation is highly sensitive to visual environment: how much time the child spends doing near work, how much time they spend in natural light, how much sleep they get, and how quickly their prescription is escalating are all signals of how their visual system is calibrating itself to its environment. A myopic progression of -0.5D or more per year is considered fast and warrants active management.

📏

The axial length number that matters

Ask your child's ophthalmologist for their axial length measurement, not just their spectacle prescription. Axial length in millimetres is the true measure of myopia progression — it tells you whether the eye is still elongating and how fast. A child whose axial length is increasing by more than 0.3mm per year is progressing rapidly and should be considered for myopia management intervention, regardless of how manageable the current prescription seems.

Layer 2 — The Global Scale

Numbers that demand attention

740M+
Children & adolescents projected to have myopia by 2050
Liang et al. · Br J Ophthalmol · Feb 2025 · 276 studies, 5.4M participants
80–90%
High school myopia rates in some East Asian cities — a glimpse of what's coming
European Journal of Public Health · Oct 2025
47%
European 20-year-olds who have myopia today vs only 13.9% in the 1960s
Eur J Public Health · Oct 2025

The 50%-by-2050 projection is not an outlier estimate from one study. It is the consensus conclusion of a 2025 comprehensive meta-analysis in the British Journal of Ophthalmology covering 276 studies and 5.4 million participants across 50 countries. The analysis found that global childhood myopia prevalence is currently approximately one-third of all children and adolescents — and rising faster in urbanised populations than in rural ones, by a factor of 2.6.

East Asia is the epicentre. In South Korea, Taiwan, Singapore, and parts of China, myopia rates among high school graduates reach 80–90%. These are not genetic outliers — the rate increase is too fast for genetics, and urban populations in other ethnicities are trending the same direction under similar environmental conditions. Europe went from 13.9% myopia in 20-year-olds in the 1960s to 47% today. The direction is universal.

The most sobering number is the progression among children using digital devices. A 2025 BMC Pediatrics systematic review specifically examining myopia in children using digital devices found the highest prevalence in East Asian urban populations — but confirmed the association globally. The prevalence is higher in girls than boys, higher in urban children than rural, and higher in older children than younger. Every single one of those factors points to accumulated near-work exposure as the driver.

🕒

Why the 2020s acceleration matters most

The COVID-19 pandemic functioned as a global natural experiment in childhood myopia risk. Lockdowns forced near-work (online learning), eliminated outdoor time, and disrupted sleep schedules simultaneously. Paediatric ophthalmologists in Bengaluru, Delhi, and major Chinese cities reported significant increases in myopia among children under 8 — an age group that was rarely affected before. The pandemic compressed years of expected prevalence increase into 18 months. The trajectory has not reversed.

Layer 3 — The Screen-Time Debate

What the evidence actually says about screens and eyes

The relationship between screens and myopia is real but misunderstood. Smartphones do not damage eyes by emitting harmful light or frequencies. The mechanism is simpler and more structural: screens keep eyes focused at close distances for extended periods, and close-distance sustained focus is one of the two primary environmental drivers of axial elongation.

It is worth being precise about this. The near-work hypothesis proposes that sustained focus on close objects signals to the developing eye that it lives in a close-distance world — and the eye elongates accordingly to optimise for that environment. Every hour of near work is an hour the eye is not receiving the signals that would encourage it to stop growing. The specific device matters less than the visual distance: a child 30cm from a book and a child 30cm from a phone are giving their eyes identical signals.

The outdoor time finding — the most important thing in this article

The single most robust, consistent finding in myopia prevention research is this: children who spend at least 2 hours per day outdoors have significantly lower rates of myopia onset and significantly slower progression once myopia begins. This finding has been confirmed across randomised controlled trials, population studies, and natural experiments across multiple continents.

The mechanism is dopamine. Natural outdoor light — even on an overcast day — is 10 to 50 times brighter than indoor artificial lighting. This light intensity triggers retinal photoreceptors to release dopamine, which acts as an inhibitor of axial elongation. Dopamine essentially tells the eye "you are already in a bright, open environment — you do not need to keep growing." Remove that signal, and the inhibition weakens.

"A Taiwanese programme promoting 2 hours of outdoor activities per weekday for kindergarten children led to a decline in myopia prevalence from 15.5% in 2014 to 8.4% in 2016 — without any change in screen-time policy."

— European Journal of Public Health · Iyer, Martin, Reijneveld · October 2025

Note what that Taiwanese finding tells us: outdoor time can halve myopia prevalence in two years, in children who continue using screens. The answer is not screen elimination. It is systematic outdoor exposure — not as a reward or a break, but as a visual health intervention equivalent to a nutritional requirement.

Two hours of outdoor time per day. Not running — walking counts. Not bright sunlight specifically — shaded outdoor light counts. The critical variable is light intensity, not activity. A child sitting under a tree reading a book outdoors is receiving significantly better myopia protection than the same child reading under indoor lighting.

📱

The honest answer on screen time

No randomised trial has proven that reducing screen time alone prevents myopia, independent of the outdoor time that screen time displaces. The screens are not the toxin. The displacement of outdoor time is. A child who uses screens heavily but also gets 2+ hours of outdoor time daily has lower myopia risk than a child with the same screen time but no outdoor exposure. Focus on the outdoor time — it is the variable the evidence is clearest about.

🇮🇳 The India Context

India is approaching the East Asian curve — and most people don't realise it yet

India has over 250 million school-age children. That number alone makes the myopia trajectory a national public health issue — not an individual optician's concern. L V Prasad Eye Institute research tracking urban Indian child myopia from 1999 to 2019 found the single most striking data point in this article: prevalence rose from 4.44% to 21.15% in 20 years. In urban populations. Among 5–15 year olds. That is a near 5-fold increase in one generation.

The COVID pandemic delivered another shock. Indian paediatric ophthalmologists reported significant new myopia cases in children under 8 — previously a rarity — during and after lockdown periods of near-constant online learning. The structural conditions that produce the East Asian epidemic (long school hours, intense academic pressure, reduced outdoor play, small urban apartments) are increasingly present across Indian cities. The epidemic phase lag between India and East Asia is narrowing.

A projection model from L V Prasad Eye Institute estimates that without active intervention, India could approach similar rates to early East Asian epidemic curves within 30 years. With 250 million children in the system, even a 5% increase in myopia prevalence translates to 12.5 million additional cases. This is not abstract epidemiology — it is a school optometry crisis in waiting.

4.44%Urban child myopia 1999
21.15%Urban child myopia 2019
250M+School-age children in India
Layer 4 — Beyond Bad Eyesight

When myopia becomes a blinding disease

High myopia is not just a stronger glasses prescription. Above -6 dioptres, it is a structural ocular pathology with dramatically elevated risk of serious, sight-threatening complications.

The language around myopia has always been reassuring. "Just nearsightedness." "Completely correctable." "Very common." All of this is true for low and moderate myopia. For high myopia — generally defined as -6 dioptres or greater — it is dangerously incomplete.

The problem is the elongated eye itself. As the eyeball stretches, the retina at the back stretches with it. Stretched retinal tissue is thinner, more fragile, and more prone to holes, tears, and detachment. The choroid — the vascular layer beneath the retina — thins and degenerates. The optic nerve head can be pulled in abnormal directions. None of this is corrected by changing the lens prescription.

🟢 0 to -3D
Low structural risk
🟡 -3 to -6D
Elevated — monitor closely
🔴 -6 to -10D
High — 10× retinal detachment risk
🚨 Beyond -10D
Pathological — MMD, legal blindness risk
  • Retinal detachment — up to 10× higher risk at high myopia vs emmetropia. Can cause sudden, permanent vision loss requiring emergency surgery.
  • Myopic macular degeneration (MMD) — the leading cause of legal blindness in working-age adults in East Asia. Caused by stretching and cracking of the Bruch's membrane beneath the macula. No reliable treatment at advanced stages.
  • Glaucoma — elevated intraocular pressure risk combined with structural optic nerve vulnerability at high myopia. 2–3× higher incidence.
  • Early cataract formation — highly myopic eyes develop lens opacity earlier than non-myopic eyes, often a decade earlier, and have significantly higher surgical complexity.

The progression from low myopia to high myopia is not inevitable. Every dioptre of progression prevented during childhood is a reduction in lifetime risk of these complications. A child who reaches adulthood at -2D instead of -6D does not just need weaker glasses — they face dramatically lower risk of blinding complications over their lifetime. This is the public health case for myopia management.

⚠️

The -3 dioptre threshold

Current research suggests that each additional dioptre of myopia beyond -3D increases complication risk non-linearly. Keeping childhood myopia below -3D is considered a meaningful clinical target — not because complications are absent below that level, but because risk increases more steeply above it. A child at -2D who is managed well and reaches adulthood without progressing is significantly better protected than one who reaches -7D having been unmanaged.

Layer 5 — Evidence-Based Action

What actually works — and what doesn't

The evidence base for myopia management has matured substantially in 2024–2026. Here is an honest assessment of what is proven, what is emerging, and what is myth.

✓ Prevention
Outdoor Time — 2+ Hours Daily
The single most evidence-backed intervention for both preventing onset and slowing progression. Light-triggered retinal dopamine inhibits axial elongation. Demonstrated in RCTs across Taiwan, China, and Europe. Works regardless of screen time reduction.
Strong Evidence
⚕ Medical
Low-Dose Atropine (0.01–0.05%)
Nightly atropine eye drops reduce myopia progression by 50–60% in multiple Asian RCTs. Now under FDA review as of Q1 2026. Side effects at low doses are minimal. Currently the strongest pharmaceutical intervention for myopia control.
Strong Evidence
⚕ Medical
Orthokeratology (Ortho-K)
Overnight rigid contact lenses that reshape the cornea during sleep. Reduce axial elongation by 30–50%. Particularly effective in children 8–14. Require careful fitting and compliance monitoring.
Strong Evidence
⚕ Medical
Defocus-Incorporated Spectacle & Contact Lenses
Specially designed optics that correct central vision while imposing controlled peripheral defocus, signalling the eye to slow elongation. 30–50% reduction in progression in multiple trials. Non-invasive and increasingly available.
Moderate–Strong
~ Limited
Screen Time Reduction Alone
No RCT has shown that screen time reduction, without increasing outdoor time, prevents myopia. The mechanism is near-work + lack of outdoor light together. Reducing screens without adding outdoor time addresses one input but misses the more important one.
Insufficient Alone
~ Emerging
Red-Light Therapy (RLRL)
Repeated low-level red light therapy (RLRL) has shown significant axial length reduction in Chinese trials — potentially reversing elongation in some cases. Still under investigation. Commercially available devices exist but require careful clinical supervision.
Emerging — Monitor
👁️

The diagnostic connection — FLUROSCÉNE and eye health monitoring

Comprehensive eye health monitoring — including corneal assessment, tear film evaluation, and surface integrity — is increasingly important in the context of myopia management. Children wearing contact lenses (ortho-K or soft lenses) require careful corneal surface monitoring. FLUROSCÉNE fluorescein strips by Agaaz Ophthalmics provide the standard tool for tear film break-up time assessment and corneal staining evaluation used by optometrists and ophthalmologists in paediatric eye care settings.

Common Questions

Frequently asked questions

The increase is too fast to be genetic — it is primarily environmental. Two factors drive it: excessive near work (sustained close-distance focus) and reduced outdoor time. Natural outdoor light triggers retinal dopamine release, which inhibits axial elongation of the eye. Children today spend dramatically less time outdoors and dramatically more time on near work than children of two or three generations ago. The combination is a near-perfect environment for myopia development during the most sensitive growth window of the visual system.

A 2025 comprehensive meta-analysis in the British Journal of Ophthalmology — covering 276 studies and 5.4 million participants across 50 countries — projects that global myopia incidence will exceed 740 million cases among children and adolescents by 2050. Including adults, overall global prevalence is expected to reach 50% — approximately 5 billion people — up from roughly 34% today and 22.9% in 2000. These numbers are not driven by East Asia alone: Europe went from 13.9% to 47% myopia in 20-year-olds between the 1960s and today.

For high myopia (above -6 dioptres), absolutely. High myopia carries up to 10× higher risk of retinal detachment, is associated with myopic macular degeneration (a leading cause of working-age blindness in East Asia), and increases glaucoma and early cataract risk by 2–3×. Glasses correct the blur. They do not stop the underlying biology — the eye remains structurally elongated and at elevated risk for these complications throughout life. This is the core argument for myopia management during childhood, when progression can still be slowed.

Yes — and this is the most robustly supported finding in myopia prevention research. Multiple randomised controlled trials confirm that 2 hours of outdoor time daily significantly reduces both myopia onset and progression. The biological mechanism is light intensity: outdoor light is 10–50× brighter than indoor lighting, triggering retinal dopamine release that inhibits axial elongation. A Taiwanese programme promoting outdoor time (without screen reduction) halved kindergarten myopia prevalence in two years. The activity does not matter much — walking, sitting, playing — the exposure to outdoor light is the therapeutic element.

India is on a trajectory that parallels the East Asian epidemic, approximately 20–30 years behind. Urban Indian child myopia rose from 4.44% in 1999 to 21.15% in 2019 — a near 5-fold increase in one generation. The pandemic accelerated this through forced near work and eliminated outdoor time. With 250 million school-age children, even small increases in prevalence translate to millions of new cases. India has not yet invested in a national myopia prevention strategy — the window for early intervention is narrowing.

Yes — and this is increasingly supported by strong clinical evidence. Low-dose atropine (0.01–0.05%) nightly eye drops reduce progression by 50–60% in multiple Asian RCTs and are under FDA review as of Q1 2026. Orthokeratology (overnight reshaping contact lenses) reduces axial elongation by 30–50%. Defocus-incorporating spectacle and contact lenses show 30–50% benefit in multiple trials. Outdoor time remains the only proven prevention strategy for onset. The ideal approach combines clinical management with environmental modification — the earlier, the more effective.

References

Peer-Reviewed Sources

  • Liang J, Pu Y, Chen J, et al. (February 2025). "Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis." British Journal of Ophthalmology, 109(3):362–371. doi:10.1136/bjo-2024-325427. [276 studies, 5.4M participants across 50 countries]
  • Iyer V, Martin D, Reijneveld SA. (October 2025). "Myopia and screen time in children: epidemic proportions." European Journal of Public Health, 35(5):809–810. doi:10.1093/eurpub/ckaf091. [Taiwanese outdoor RCT data and European trends]
  • Salari N, Molaeefar S, Abdolmaleki A, et al. (April 2025). "Global prevalence of myopia in children using digital devices: a systematic review and meta-analysis." BMC Pediatrics, 25:325. doi:10.1186/s12887-025-05684-8.
  • Priscilla JJ, Verkicharla PK. (2021). "Time trends on the prevalence of myopia in India — a prediction model for 2050." Ophthalmic and Physiological Optics, 41(3):466–474. doi:10.1111/opo.12806. [L V Prasad Eye Institute — 4.44% to 21.15% India data]
  • Agarwal A. (November 2025). "What's driving the alarming rise of myopia in Indian children?" Healthcare Radius. [Urban India myopia analysis, 250M children context]
  • Fricke TR, Jong M, Naidoo KS, et al. (2018). "Global prevalence of visual impairment associated with myopic macular degeneration." British Journal of Ophthalmology, 102(7):855–862. [MMD blindness risk data]
  • Bullimore MA, Brennan NA. (2019). "Myopia control: why each diopter matters." Optometry and Vision Science, 96(6):463–465. [Risk escalation per dioptre data]
  • Ophthalmology Times Europe. (April 2026). "Myopia's global impact, by the numbers." [Epidemiological synthesis, 22.9% to 34% global trend]

Healthy eyes start with
the right diagnostics.

Agaaz Ophthalmics manufactures FLUROSCÉNE fluorescein diagnostic strips — used for corneal surface assessment and tear film evaluation in paediatric eye care and contact lens monitoring. Manufactured in Ahmedabad, exported to 15+ countries.

Start writing here...